New ASCO Guideline Recommends Germline Testing in ALL Newly Diagnosed Breast Cancer Patients 65 Years or Younger
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
FDA Approves ALECENSA® as Adjuvant Treatment for ALK-Positive Non Small Cell Lung Cancer
Long Term Benefits of RUBRACA® Maintenance in Newly Diagnosed Ovarian Cancer
Omitting Axillary Lymph Node Dissection in Breast Cancer with Sentinel-Node Metastases
FDA Approves ENHERTU® for Unresectable or Metastatic HER2-Positive Solid Tumors
April 2024: Current Tumor-Agnostic Therapies
Enfortumab Vedotin plus Pembrolizumab: A Breakthrough in Locally Advanced or Metastatic Urothelial Carcinoma
Novel Prognostic Factors for Treatment-Free Remission in Chronic Myeloid leukemia
Neoadjuvant KEYTRUDA® plus Chemotherapy Significantly Improves EFS in Early Stage High Risk Triple Negative Breast Cancer
Metformin May Reduce the Risk of Cancers, Especially GI Malignancies
FDA Approves BREYANZI®, First CAR-T Cell Therapy for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
FDA Approves TEVIMBRA® for Advanced Esophageal Squamous Cell Carcinoma
FDA Approves RYBREVANT® in Combination with Chemotherapy for Advanced NSCLC with EGFR Exon 20 Insertion Mutations
FDA Approves OPDIVO® in Combination with Chemotherapy for the First Line Treatment of Advanced Urothelial Carcinoma
Stockholm3 Blood Test Identifies Aggressive Prostate Cancer
FDA Approves ONIVYDE® for First-Line Treatment of Metastatic Pancreatic Adenocarcinoma
Circulating Tumor DNA Can be Used as an Early Marker of Immunotherapy Response
Late Breaking Abstract – 2024 ASCO GU Cancers Symposium: Adjuvant KEYTRUDA® Improves Overall Survival in Renal cell Carcinoma
Pregnancy after Breast Cancer Treatment in BRCA Carriers
Bottom Ad
Advertisement
Subscribe
